All Pathways
Family MedicineManagement

Type 2 Diabetes Initial Workup & Management (ADA 2025)

Type 2 Diabetes Initial Workup & Management (ADA 2025): New Diagnosis Type 2 Diabetes → Initial Evaluation → Cardiovascular/Renal Risk Assessment → High...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    New Diagnosis Type 2 Diabetes

    Confirmed by A1c ≥6.5%, FPG ≥126, or 2h-OGTT ≥200

    1. Action

      Initial Evaluation

      Comprehensive metabolic assessment

      • A1c (confirms diagnosis, baseline)
      • Lipid panel (CV risk)
      • Comprehensive metabolic panel
      • Urinalysis + urine albumin/creatinine
      • Foot exam, fundoscopy referral
      1. Decision

        Cardiovascular/Renal Risk Assessment

        Determines medication priority

        • Established ASCVD?
        • Heart failure present?
        • CKD (eGFR <60 or albuminuria)?
        • Multiple CV risk factors?
        1. Action

          High CV/Renal Risk

          GLP-1 RA or SGLT2i priority

          • Add GLP-1 RA (semaglutide, liraglutide) for ASCVD
          • Add SGLT2i (empagliflozin, dapagliflozin) for HF/CKD
          • Independent of A1c, add to metformin
          • Both classes have proven CV/renal benefits
          1. Decision

            A1c Recheck at 3 Months

            Assess response to therapy

            • Target: <7% for most adults
            • <6.5% if young, no hypoglycemia risk
            • <8% if elderly, frail, limited life expectancy
            1. Outcome

              At A1c Goal

              Continue current regimen, monitor every 3-6 months

            2. Action

              Add Second Agent

              Intensify therapy if above goal

              • Preferred: GLP-1 RA or SGLT2i
              • Alternatives: DPP-4i, TZD, sulfonylurea
              • Consider cost, side effects, patient preference
              • Avoid SU + insulin (hypoglycemia risk)
            3. Action

              Add Third Agent or Insulin

              Triple therapy or basal insulin

              • If still above goal on 2 agents
              • Consider basal insulin (start 10U or 0.1-0.2 U/kg)
              • Titrate by 2U every 3 days to FPG goal
              • Can add to GLP-1 RA + metformin
        2. Action

          Low CV Risk

          Focus on glycemic control

          • Start metformin 500mg BID
          • Titrate to 1000mg BID over 1-2 months
          • If A1c >9%, consider dual therapy upfront
          • Lifestyle modification essential
      2. Action

        Complication Screening

        Annual assessments

        • Dilated eye exam annually
        • Foot exam each visit
        • BP goal <130/80
        • Statin for ages 40-75
        • UACR annually
      3. Action

        Lifestyle Interventions

        Foundation of all therapy

        • Medical nutrition therapy referral
        • 150 min/week moderate activity
        • Weight loss goal 5-10%
        • Smoking cessation
        • Diabetes self-management education

Guideline Source

ADA Standards of Care in Diabetes 2025

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Does not address Type 1 diabetes or LADA
  • Insulin dosing requires individualization
  • Renal dosing adjustments not detailed
  • Does not address pediatric T2DM
  • GLP-1 RA/SGLT2i contraindications require review

Contraindicated Populations

pediatricpregnancy

Applicable Regions

USAUEU

AU: RACGP guidelines largely align with ADA

EU: EASD/ADA consensus applies

US: Based on ADA 2025 Standards of Care

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the Type 2 Diabetes Initial Workup & Management (ADA 2025)?

The Type 2 Diabetes Initial Workup & Management (ADA 2025) is a management clinical algorithm for Family Medicine. It provides a structured decision tree to guide clinical decision-making, based on ADA Standards of Care in Diabetes 2025.

What guideline is the Type 2 Diabetes Initial Workup & Management (ADA 2025) based on?

This algorithm is based on ADA Standards of Care in Diabetes 2025 (DOI: 10.2337/dc25-SINT).

What are the limitations of the Type 2 Diabetes Initial Workup & Management (ADA 2025)?

Known limitations include: Does not address Type 1 diabetes or LADA; Insulin dosing requires individualization; Renal dosing adjustments not detailed; Does not address pediatric T2DM; GLP-1 RA/SGLT2i contraindications require review. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Type 2 Diabetes Initial Workup & Management (ADA 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free